Evidence map›Paper›PMID 40842416›Full record

ArticleThe Journal of pathology2025

Characteristic miRNA profiles represent clinicopathological diversity of small cell lung cancer.

Masafumi Horie, Hiroshi Takumida, Hayato Koba, Tsukasa Ueda, Hidenori Tanaka, Masami Suzuki, Yukinobu Ito, Ayumi Ito, Mao Kondo, Hiroshi I Suzuki and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Masafumi HorieDivision of Molecular and Genomic Pathology, Department of Pathology, Kobe University Graduate School of Medicine, Kobe, Japan.
Hiroshi TakumidaDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hayato KobaDepartment of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.ORCID 0000-0002-7443-5432
Tsukasa UedaDepartment of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Hidenori TanakaDepartment of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Masami SuzukiDepartment of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Yukinobu ItoDepartment of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Ayumi ItoDepartment of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Mao KondoDepartment of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Hiroshi I SuzukiDivision of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Isao MatsumotoDepartment of Thoracic Surgery, Kanazawa University, Kanazawa, Japan.
Seiji YanoDepartment of Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Akira SaitoDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Daichi MaedaDepartment of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.

Funding

Grant for Lung Cancer ResearchJapan Society for the Promotion of Science 16H06279Japan Society for the Promotion of Science 23K07649Japan Society for the Promotion of Science JP22H04925Takeda Science Foundation
6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is classified into distinct molecular subtypes based on the expression patterns of four transcription regulators: achaete-scute homolog 1 (ASCL1), neuronal differentiation 1 (NEUROD1), POU class 2 homeobox 3 (POU2F3), and yes-associated protein 1 (YAP1). MicroRNAs (miRNAs) play critical roles in cancer cellular processes but their subtype-specific implications in SCLC remain underexplored. Out of 46 surgically resected SCLC samples, miRNA visualization through in situ hybridization identified high expression of miR-375 in the ASCL1, NEUROD1, and ASCL1/NEUROD1 subtypes, and miR-9-5p in the POU2F3 subtype. Comprehensive enhancer profiling using SCLC cell lines indicated that miR-375 and miR-9-5p were regulated by super-enhancers in a subtype-specific manner. Multiplex immunohistochemistry by imaging mass cytometry found that the miR-9-5p-high SCLC was characterized by a higher stromal area ratio, increased numbers of CD8

Indexed as

Biomarkers, TumorLung NeoplasmsMicroRNAsSmall Cell Lung CarcinomaAgedBasic Helix-Loop-Helix ProteinsCell Line, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedYAP-Signaling ProteinsASCL1 protein, humanBasic Helix-Loop-Helix ProteinsBiomarkers, TumorMicroRNAsMIRN375 microRNA, humanMIRN92 microRNA, humanNEUROD1 protein, humanYAP1 protein, humanYAP-Signaling Proteinsimaging mass cytometrymiR‐375miR‐9‐5pmiRNASCLCsuper‐enhancertumor microenvironment

Identifiers

PMID40842416
PMCPMC12438024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.